Non-invasive Screening for Significant Liver Disease  

References

  1. Predicting Liver- Related Outcomes in People With Nonalcoholic Fatty Liver Disease: The Prognostic Value of Noninvasive Fibrosis Tests. Johnson AL, Hayward KL,Patel Preya et al.Hepatology Communications 2022;6:728-739.
  2. Population screening for liver fibrosis: Towards early diagnosis and intervention for chronic liver disease. Gines P, Castera L, Lammert F et al.Hepatology 2022;75:219-228
  3. Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review.Harris R, Harman JD, Card TR, Aithal G et al.Lancet Gastroenterol Hepatol .Published online January 31, 2017
  4. Ability of Noninvasive Scoring Systems to Identify Individuals in the Population at Risk for Severe Liver Disease..Hagstorm H, Talback M, Andreasson A et al.Gastroenterology 2020;158:200-214
  5. Role of Noninvasive Tests in Clinical Gastroenterology Practices to identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverese Outcomes: Expert Panel Recommendations. Younossi ZM, Noureddin M,Bernstein D et al. Am J Gastroenterol 20221;116:254-262
  6. Direct Comparison of US and MR Elastography for Staging Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. Kento Imajo, Yasushi Honda, Takashi Kobayashi et al. Clinical Gastroenterology and Hepatology 2022;20:908-917

All Rights Reserved with Dr. Parijat Gupte.  |  Privacy Policy  |  Developed by 560mTEK.